Diisopropylethylamine → 2-[[1-cyclohexyl-2-(3-phenylquinoxalin-6-yl)benzimidazole-5-carbonyl]amino]-3-(5-hydroxy-1H-indol-3-yl)propanoic acid

HRID 1788420

반응식

HRID 1788420 반응식
[CH:1]1([N:7]2[C:11]3[CH:12]=[CH:13][C:14]([C:16](O)=[O:17])=[CH:15][C:10]=3[N:9]=[C:8]2[C:19]2[CH:20]=[C:21]3[C:26](=[CH:27][CH:28]=2)[N:25]=[CH:24][C:23]([C:29]2[CH:34]=[CH:33][CH:32]=[CH:31][CH:30]=2)=[N:22]3)[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C.[OH:68][C:69]1[CH:83]=[C:82]2[C:72]([NH:73][CH:74]=[C:75]2[CH2:76][C@@H:77]([C:79]([OH:81])=[O:80])[NH2:78])=[CH:71][CH:70]=1>CN(C=O)C>[CH:1]1([N:7]2[C:11]3[CH:12]=[CH:13][C:14]([C:16]([NH:78][CH:77]([CH2:76][C:75]4[C:82]5[C:72](=[CH:71][CH:70]=[C:69]([OH:68])[CH:83]=5)[NH:73][CH:74]=4)[C:79]([OH:81])=[O:80])=[O:17])=[CH:15][C:10]=3[N:9]=[C:8]2[C:19]2[CH:20]=[C:21]3[C:26](=[CH:27][CH:28]=2)[N:25]=[CH:24][C:23]([C:29]2[CH:30]=[CH:31][CH:32]=[CH:33][CH:34]=2)=[N:22]3)[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1

참가 물질

6

반응물 4

HCID 81531Diisopropylethylamine2회HCID 439280L-5-HydroxytryptophanHCID 2733084Methanaminium, N-((1H-benzotriazol-1-yloxy)(dimethylamino)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 5275974HCID 5275974, 화합물

생성물 1

HCID 52761612-[[1-cyclohexyl-2-(3-phenylquinoxalin-6-yl)benzimidazole-5-carbonyl]amino]-3-(5-hydroxy-1H-indol-3-yl)propanoic acid

시약·촉매·용매 1

HCID 6228Dimethylformamide용매2회

실험 절차

Compound 205 (100 mg, 0.22 mmol) was activated in 2 mL of DMF with 92 mg (0.24 mmol) of HBTU and 85 μL of DIEA for 10 minutes at room temperature. 5-hydroxy-L-tryptophane (56 mg) dissolved in 1 mL DMF was added, followed by 44 μL of DIEA. The mixture was stirred at room temperature for 1 h, then was evaporated to dryness. The oil was purified using RP-HPLC column to give the pure Compound 236.

후처리

  1. additionwas added
  2. customwas evaporated to dryness
  3. customThe oil was purified

출처 및 근거

ORD 기록
ord-0105d45447284ad8ba813b9a863a705c
출처 데이터셋
uspto-grants-2009_03
특허 번호
US07511145B2

연결된 노트

불러오는 중…